Communiqués BioHarvest Sciences Inc. Canadian Securities Exchange

Actions

BHSC

CA13767B1013

Produits pharmaceutiques

Temps Différé Canadian Securities Exchange Autres places de cotation 16:24:58 05/10/2021			Varia. 5j.	Varia. 1 janv.
0,3500 ^CAD	+6,06 %		-2,94 %	+46,67 %

18/05	Tate & Lyle et BioHarvest Sciences renforcent leur collaboration pour le développement de molécules édulcorantes végétales de nouvelle génération	CI
14/05	BioHarvest Sciences Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

18/06	BioHarvest Sciences to Present at the 2026 BIO International Convention	NE
18/05	Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation	NE
14/05	BioHarvest Sciences : First Quarter 2026 Financial Statements	PU
14/05	BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update	NE
13/05	BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division	NE
13/05	BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications	NE
12/05	BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform	NE
01/05	BioHarvest Sciences : BHST May 2026 Investor Presentation	PU
30/04	BioHarvest Sciences to Report First Quarter 2026 Financial Results on May 14, 2026	NE
29/04	BioHarvest Sciences Announces Strategic Leadership Transition with Dr. Zaki Rakib Assuming Role of Chief Executive Officer to Accelerate "Two-Lens" Growth Strategy	NE
31/03	BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results	NE
31/03	BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform	NE
26/03	BioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United States	NE
17/03	BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026	NE
13/03	BioHarvest Sciences Announces Grant of Long-Term Incentive Awards to Employees, Officers and Directors	NE
05/03	BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy	NE
03/03	BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026	NE
07/01	BioHarvest Sciences Issues Year End Shareholder Letter	NE
18/12	BioHarvest Sciences Awarded $1.6 Million USD Grant from the Israeli Innovation Authority to Advance Second-Generation Botanical Synthesis Platform	NE
03/12	BioHarvest Sciences Announces Launch of VINIA Blood Flow Hydration Product	NE
13/11	BioHarvest Sciences : BHST November 2025 Investor Presentation	PU
13/11	BioHarvest Sciences Reports Third Quarter 2025 Financial Results	NE
12/11	BioHarvest Sciences to Attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025	NE
10/11	BioHarvest Sciences Announces Closing of $19.9 Million Upsized Public Offering of Common Stock and Exercise of Underwriter's Option to Purchase Additional Shares	NE
07/11	BioHarvest Sciences Announces Pricing of $17.4 Million Upsized Public Offering of Common Stock	NE